To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.
April 1-5th, 2017 | Washington, USA | AACR Annual Meeting
XenTech will be attending the 2017 AACR annual meeting in Washington. Come and visit us at booth #343 and poster sessions ! Poster # 3856 : Identification of circulating tumour cells in breast cancer patient-derived xenograft models Session Date and Time: Tuesday Apr 4, 2017 8:00 AM 12:00 PM Poster # 4936 : […]
Contract Research Organization
XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....